Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need
- First patient completed observation period following PBGENE-DMD treatment with no reported safety concerns -
- Independent Data Safety Monitoring Board endorses proceeding with dosing additional patients
-Phase 1 ELIMINATE-B study successful, PBGENE-HBV Program Advancing to Phase 2-
-PBGENE-HBV achieves target product profile at 0.4 mg/kg dose-
-PBGENE-HBV achieved pgRNA loss to undetectable in 100% of evaluable
- PBGENE-HBV late-breaking oral presentation for ELIMINATE-B trial at AASLD's The Liver Meeting® 2026 on November 8; data abstract scheduled for release November 5 -
- Dosed first patient with PBGENE-DMD at
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced
Phase 1/2 dosing completed across all dose cohorts; participant evaluations ongoing
Preliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safety events
-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD –
-First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care
iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, in vivo targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced that data from the ongoing
- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL,
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced
– Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy –
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced
- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -
- In the <1% of cccDNA remaining,
